vs
丰田北美（MPAA）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是丰田北美的1.2倍（$197.9M vs $167.7M），REPLIGEN CORP净利率更高（6.7% vs 1.1%，领先5.7%），REPLIGEN CORP同比增速更快（13.6% vs -9.9%），REPLIGEN CORP自由现金流更多（$17.6M vs $-8.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -5.9%）
丰田北美（TMNA）是丰田汽车旗下负责加拿大、墨西哥及美国全境业务的运营子公司，业务范围覆盖研发、生产制造、销售营销、售后及企业管理等板块，相关核心业务由TMNA统筹，部分板块由其他子公司及控股企业负责执行，公司总部位于得克萨斯州普莱诺，在肯塔基州乔治敦等多地设有分支机构。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
MPAA vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.2倍
$167.7M
营收增速更快
RGEN
高出23.6%
-9.9%
净利率更高
RGEN
高出5.7%
1.1%
自由现金流更多
RGEN
多$26.2M
$-8.6M
两年增速更快
RGEN
近两年复合增速
-5.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $167.7M | $197.9M |
| 净利润 | $1.8M | $13.3M |
| 毛利率 | 19.6% | 52.5% |
| 营业利润率 | 5.0% | 9.0% |
| 净利率 | 1.1% | 6.7% |
| 营收同比 | -9.9% | 13.6% |
| 净利润同比 | -22.4% | 143.9% |
| 每股收益（稀释后） | $0.09 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MPAARGEN
| Q4 25 | $167.7M | $197.9M | ||
| Q3 25 | $221.5M | $188.8M | ||
| Q2 25 | $188.4M | $182.4M | ||
| Q1 25 | $193.1M | $169.2M | ||
| Q4 24 | $186.2M | $174.1M | ||
| Q3 24 | $208.2M | $154.9M | ||
| Q2 24 | $169.9M | $154.1M | ||
| Q1 24 | $189.5M | $151.3M |
净利润MPAARGEN
| Q4 25 | $1.8M | $13.3M | ||
| Q3 25 | $-2.1M | $14.9M | ||
| Q2 25 | $3.0M | $14.9M | ||
| Q1 25 | $-722.0K | $5.8M | ||
| Q4 24 | $2.3M | $-30.3M | ||
| Q3 24 | $-3.0M | $-654.0K | ||
| Q2 24 | $-18.1M | $3.3M | ||
| Q1 24 | $1.3M | $2.1M |
毛利率MPAARGEN
| Q4 25 | 19.6% | 52.5% | ||
| Q3 25 | 19.3% | 53.2% | ||
| Q2 25 | 18.0% | 50.0% | ||
| Q1 25 | 19.9% | 53.6% | ||
| Q4 24 | 24.1% | 26.1% | ||
| Q3 24 | 19.8% | 50.0% | ||
| Q2 24 | 17.2% | 49.8% | ||
| Q1 24 | 18.4% | 49.5% |
营业利润率MPAARGEN
| Q4 25 | 5.0% | 9.0% | ||
| Q3 25 | 7.4% | 8.9% | ||
| Q2 25 | 10.7% | 7.6% | ||
| Q1 25 | 8.4% | 3.9% | ||
| Q4 24 | 9.4% | -17.7% | ||
| Q3 24 | 6.0% | -5.1% | ||
| Q2 24 | -3.8% | 1.0% | ||
| Q1 24 | 6.4% | 1.3% |
净利率MPAARGEN
| Q4 25 | 1.1% | 6.7% | ||
| Q3 25 | -1.0% | 7.9% | ||
| Q2 25 | 1.6% | 8.2% | ||
| Q1 25 | -0.4% | 3.4% | ||
| Q4 24 | 1.2% | -17.4% | ||
| Q3 24 | -1.4% | -0.4% | ||
| Q2 24 | -10.6% | 2.2% | ||
| Q1 24 | 0.7% | 1.4% |
每股收益（稀释后）MPAARGEN
| Q4 25 | $0.09 | $0.24 | ||
| Q3 25 | $-0.11 | $0.26 | ||
| Q2 25 | $0.15 | $0.26 | ||
| Q1 25 | $-0.03 | $0.10 | ||
| Q4 24 | $0.11 | $-0.55 | ||
| Q3 24 | $-0.15 | $-0.01 | ||
| Q2 24 | $-0.92 | $0.06 | ||
| Q1 24 | $0.06 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.6M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $258.5M | $2.1B |
| 总资产 | $991.3M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资MPAARGEN
| Q4 25 | $19.6M | $767.6M | ||
| Q3 25 | $17.7M | $748.7M | ||
| Q2 25 | $14.5M | $708.9M | ||
| Q1 25 | $11.3M | $697.2M | ||
| Q4 24 | $12.7M | $757.4M | ||
| Q3 24 | $12.3M | $784.0M | ||
| Q2 24 | $9.4M | $809.1M | ||
| Q1 24 | $15.8M | $780.6M |
总债务MPAARGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MPAARGEN
| Q4 25 | $258.5M | $2.1B | ||
| Q3 25 | $258.5M | $2.1B | ||
| Q2 25 | $260.1M | $2.1B | ||
| Q1 25 | $257.7M | $2.0B | ||
| Q4 24 | $262.7M | $2.0B | ||
| Q3 24 | $264.0M | $2.0B | ||
| Q2 24 | $267.2M | $2.0B | ||
| Q1 24 | $285.1M | $2.0B |
总资产MPAARGEN
| Q4 25 | $991.3M | $2.9B | ||
| Q3 25 | $990.0M | $2.9B | ||
| Q2 25 | $973.4M | $2.9B | ||
| Q1 25 | $957.6M | $2.9B | ||
| Q4 24 | $949.5M | $2.8B | ||
| Q3 24 | $986.2M | $2.8B | ||
| Q2 24 | $978.0M | $2.9B | ||
| Q1 24 | $1.0B | $2.8B |
负债/权益比MPAARGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-8.6M | $17.6M |
| 自由现金流率自由现金流/营收 | -5.2% | 8.9% |
| 资本支出强度资本支出/营收 | 0.2% | 4.1% |
| 现金转化率经营现金流/净利润 | -4.63× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $27.7M | $93.9M |
8季度趋势，按日历期对齐
经营现金流MPAARGEN
| Q4 25 | $-8.2M | $25.7M | ||
| Q3 25 | $21.9M | $48.1M | ||
| Q2 25 | $10.0M | $28.6M | ||
| Q1 25 | $9.1M | $15.0M | ||
| Q4 24 | $34.4M | $39.2M | ||
| Q3 24 | $22.9M | $49.3M | ||
| Q2 24 | $-20.8M | $42.2M | ||
| Q1 24 | $-9.3M | $44.7M |
自由现金流MPAARGEN
| Q4 25 | $-8.6M | $17.6M | ||
| Q3 25 | $20.8M | $43.4M | ||
| Q2 25 | $9.2M | $21.5M | ||
| Q1 25 | $6.2M | $11.4M | ||
| Q4 24 | $33.7M | $33.6M | ||
| Q3 24 | $22.3M | $42.3M | ||
| Q2 24 | $-21.3M | $37.4M | ||
| Q1 24 | $-9.8M | $36.4M |
自由现金流率MPAARGEN
| Q4 25 | -5.2% | 8.9% | ||
| Q3 25 | 9.4% | 23.0% | ||
| Q2 25 | 4.9% | 11.8% | ||
| Q1 25 | 3.2% | 6.8% | ||
| Q4 24 | 18.1% | 19.3% | ||
| Q3 24 | 10.7% | 27.3% | ||
| Q2 24 | -12.6% | 24.3% | ||
| Q1 24 | -5.2% | 24.0% |
资本支出强度MPAARGEN
| Q4 25 | 0.2% | 4.1% | ||
| Q3 25 | 0.5% | 2.5% | ||
| Q2 25 | 0.4% | 3.9% | ||
| Q1 25 | 1.5% | 2.1% | ||
| Q4 24 | 0.4% | 3.2% | ||
| Q3 24 | 0.3% | 4.5% | ||
| Q2 24 | 0.3% | 3.1% | ||
| Q1 24 | 0.3% | 5.5% |
现金转化率MPAARGEN
| Q4 25 | -4.63× | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | 3.30× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | 15.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | -6.93× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MPAA
| Reportable Segment Aggregation Before Other Operating Segment | $156.3M | 93% |
| Other | $11.4M | 7% |
RGEN
暂无分部数据
